CA3182015A1 - Sulcardine administration for treatment of acute atrial fibrillation - Google Patents
Sulcardine administration for treatment of acute atrial fibrillation Download PDFInfo
- Publication number
- CA3182015A1 CA3182015A1 CA3182015A CA3182015A CA3182015A1 CA 3182015 A1 CA3182015 A1 CA 3182015A1 CA 3182015 A CA3182015 A CA 3182015A CA 3182015 A CA3182015 A CA 3182015A CA 3182015 A1 CA3182015 A1 CA 3182015A1
- Authority
- CA
- Canada
- Prior art keywords
- sulcardine
- pharmaceutically acceptable
- acceptable salt
- administration
- tmax
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038664P | 2020-06-12 | 2020-06-12 | |
| US63/038,664 | 2020-06-12 | ||
| PCT/US2021/037098 WO2021252959A1 (en) | 2020-06-12 | 2021-06-11 | Sulcardine administration for treatment of acute atrial fibrillation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3182015A1 true CA3182015A1 (en) | 2021-12-16 |
Family
ID=78824214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3182015A Pending CA3182015A1 (en) | 2020-06-12 | 2021-06-11 | Sulcardine administration for treatment of acute atrial fibrillation |
Country Status (14)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11813245B2 (en) * | 2020-06-12 | 2023-11-14 | Huyabio International, Llc | Sulcardine administration for treatment of acute atrial fibrillation |
| WO2026036095A1 (en) * | 2024-08-08 | 2026-02-12 | Huyabio International, Llc | J-Tp PROTECTION |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1172908C (zh) * | 1999-12-10 | 2004-10-27 | 中国科学院上海药物研究所 | N-取代苄基或苯基芳香磺酰胺化合物及其用途 |
| CN1939298A (zh) | 2005-09-29 | 2007-04-04 | 中国科学院上海药物研究所 | 硫酸舒欣啶固体和靶向制剂及其制备方法 |
| US8541464B2 (en) * | 2009-11-17 | 2013-09-24 | HUYA Biosciences International LLC | Treatment of atrial fibrillation |
| WO2011062903A2 (en) * | 2009-11-17 | 2011-05-26 | Elliott Gary T | Slow infusion of sulcardine and its salts |
| EP3302442B1 (en) | 2015-06-03 | 2024-10-16 | Triastek, Inc. | Dosage forms and use thereof |
| AU2017261372B2 (en) | 2016-05-05 | 2019-02-14 | Triastek, Inc. | Controlled release dosage form |
| AU2018212273B2 (en) | 2017-01-26 | 2023-12-21 | Triastek, Inc. | Dosage forms of controlled release at specific gastrointestinal sites |
| WO2020123824A1 (en) * | 2018-12-13 | 2020-06-18 | Huya Bioscience International, Llc | Sulcardine administration for treatment of acute atrial fibrillation |
| KR102405199B1 (ko) * | 2019-01-29 | 2022-06-02 | 후야 바이오사이언스 인터내셔널 엘엘씨 | 설카딘 염 |
| US11813245B2 (en) * | 2020-06-12 | 2023-11-14 | Huyabio International, Llc | Sulcardine administration for treatment of acute atrial fibrillation |
-
2021
- 2021-06-11 US US17/345,564 patent/US11813245B2/en active Active
- 2021-06-11 CN CN202180055470.6A patent/CN116723836A/zh active Pending
- 2021-06-11 JP JP2022575898A patent/JP2023529196A/ja active Pending
- 2021-06-11 PH PH1/2022/553396A patent/PH12022553396A1/en unknown
- 2021-06-11 MX MX2022015834A patent/MX2022015834A/es unknown
- 2021-06-11 WO PCT/US2021/037098 patent/WO2021252959A1/en not_active Ceased
- 2021-06-11 EP EP21823026.6A patent/EP4164633A4/en active Pending
- 2021-06-11 BR BR112022025216A patent/BR112022025216A2/pt unknown
- 2021-06-11 KR KR1020237000723A patent/KR20230024347A/ko active Pending
- 2021-06-11 CA CA3182015A patent/CA3182015A1/en active Pending
- 2021-06-11 IL IL298907A patent/IL298907A/en unknown
- 2021-06-11 AU AU2021288056A patent/AU2021288056A1/en active Pending
-
2022
- 2022-12-09 CL CL2022003501A patent/CL2022003501A1/es unknown
-
2023
- 2023-01-10 CO CONC2023/0000194A patent/CO2023000194A2/es unknown
- 2023-10-11 US US18/484,823 patent/US12465587B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11813245B2 (en) | 2023-11-14 |
| US20240058304A1 (en) | 2024-02-22 |
| PH12022553396A1 (en) | 2024-04-22 |
| IL298907A (en) | 2023-02-01 |
| EP4164633A4 (en) | 2024-07-31 |
| WO2021252959A1 (en) | 2021-12-16 |
| JP2023529196A (ja) | 2023-07-07 |
| CL2022003501A1 (es) | 2023-06-09 |
| KR20230024347A (ko) | 2023-02-20 |
| BR112022025216A2 (pt) | 2023-04-04 |
| EP4164633A1 (en) | 2023-04-19 |
| US12465587B2 (en) | 2025-11-11 |
| CN116723836A (zh) | 2023-09-08 |
| US20210386708A1 (en) | 2021-12-16 |
| AU2021288056A1 (en) | 2023-02-09 |
| CO2023000194A2 (es) | 2023-03-27 |
| MX2022015834A (es) | 2023-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11883380B2 (en) | Sulcardine administration for treatment of acute atrial fibrillation | |
| RU2334513C2 (ru) | Фармацевтические композиции, включающие валсартан и ингибиторы нейтральной эндопептидазы (nep) | |
| US12465587B2 (en) | Sulcardine administration for treatment of acute atrial fibrillation | |
| US8569325B2 (en) | Method of treatment with coadministration of aspirin and prasugrel | |
| KR20160108611A (ko) | 심방세동의 치료 방법 | |
| EP2133074A1 (en) | Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation | |
| CN102869357A (zh) | 舒欣啶及其盐的缓慢滴注 | |
| JP2011518147A (ja) | 血中カリウム濃度を調節する薬剤を調製するためのドロネダロンまたは医薬的に許容されるこの塩の使用 | |
| EP2133075A1 (en) | Use of dronedarone for the preparation of a medicament intended for the prevention of cardioversion | |
| US20260041665A1 (en) | J-Tp Protection | |
| EA045624B1 (ru) | Введение сулькардина для лечения острой фибрилляции предсердий | |
| HK40061591A (en) | Sulcardine administration for treatment of acute atrial fibrillation | |
| MXPA01012638A (es) | Derivados de aminotetralina para la terapia de enfermedades cardiovasculares. | |
| WO2024086819A2 (en) | Diagnosis and treatment of heart failure | |
| HK1155668A (en) | Dronedarone for the prevention of permanent atrial fibrillation | |
| HK1155667A (en) | Dronedarone for the prevention of cardioversion | |
| TW201200131A (en) | Use of dronedarone for the preparation of a medicament for the prevention of cardiovacular hospitalizations or death or cardiovascular events in patients with premanent atrial fibrillation | |
| HK1156503A (en) | Combination of dronedarone with at least one diuretic, and therapeutic use thereof | |
| HK1176859A (en) | Treatment of atrial fibrillation | |
| HK1176859B (en) | Treatment of atrial fibrillation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250522 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250522 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250522 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250523 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250606 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250606 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250807 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250807 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250807 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250807 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250807 |